KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Other Operating Expenses (2018 - 2025)

Emergent BioSolutions' Other Operating Expenses history spans 10 years, with the latest figure at $12.2 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses changed N/A year-over-year to $12.2 million; the TTM value through Sep 2025 reached -$12.2 million, down 150.21%, while the annual FY2024 figure was $24.3 million, 67.25% down from the prior year.
  • Other Operating Expenses reached $12.2 million in Q4 2025 per EBS's latest filing, up from -$12.2 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $305.2 million in Q4 2021 to a low of -$40.0 million in Q2 2024.
  • Average Other Operating Expenses over 5 years is $111.0 million, with a median of $94.6 million recorded in 2021.
  • The largest YoY upside for Other Operating Expenses was 9285.71% in 2024 against a maximum downside of 153.4% in 2024.
  • A 5-year view of Other Operating Expenses shows it stood at $305.2 million in 2021, then plummeted by 44.33% to $169.9 million in 2022, then tumbled by 100.41% to -$700000.0 in 2023, then soared by 9285.71% to $64.3 million in 2024, then crashed by 81.03% to $12.2 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Other Operating Expenses are $12.2 million (Q4 2025), -$12.2 million (Q1 2025), and $64.3 million (Q3 2024).